



****REPRESENTATIVE DATASHEET****

Matched-Pair Antibody Set for ELISA of human α_1 Antitrypsin antigen (α_1 AT)

Sufficient reagent for **5 x 96 well** plates

Product #: A1AT-EIA
Lot #: SAMPLE
Expiry Date: SAMPLE

Store at **-10 to -20 °C**

For Research Use Only
Not for use in diagnostic procedures.

Description of α_1 Antitrypsin (α_1 AT)

α_1 Antitrypsin (α_1 AT), also known as α_1 Proteinase inhibitor (α_1 PI), is the most abundant protease inhibitor in blood and a member of the SERPIN family of proteinase inhibitors. Serum levels are typically 1.3 mg/ml (2.5 μ M) but α_1 AT is an acute phase protein and concentrations can rise four-fold during inflammatory episodes or tissue injury. Low levels in circulation have been associated with pulmonary disease such as emphysema. α_1 AT is a single chain molecule with a mass of 52,000 daltons that is produced primarily in the liver and to a lesser extent by blood monocytes and intestinal epithelium. Based on association rates, the primary target enzyme for α_1 AT is believed to be neutrophil elastase^{1,2}, but α_1 AT is a broad-spectrum inhibitor for many serine proteinases and the main role of α_1 AT *in vivo* is likely that of a "backup" inhibitor and proteinase scavenger in fluids and tissues. Although the association rates of α_1 AT with other enzymes are lower, the high concentration in plasma makes it an important inhibitor of activated Protein C, activated F.XI, thrombin and plasmin¹⁻⁴. Enzyme inhibition by α_1 AT occurs through proteolytic cleavage between Met³⁵⁸ and Ser³⁵⁹, which induces a conformational change in α_1 AT locking the enzyme into a stable, inactive 1:1 enzyme-inhibitor complex.

Principle of Sandwich-style ELISA

Affinity-purified antibody to α_1 AT is coated onto the wells of a microtitre plate. Any remaining binding sites on the plastic wells are blocked with an excess of bovine serum albumin. The plates are washed and plasma or other fluids containing α_1 AT are applied. The coated antibody will capture the α_1 AT in the sample. After washing the plate to remove unbound material, a peroxidase conjugated second antibody to α_1 AT is added to the plate to bind to the captured α_1 AT. After washing the plate to remove unbound conjugated antibody, the peroxidase activity is expressed by incubation with o-phenylenediamine (OPD). After a fixed development time the reaction is quenched with the addition of H₂SO₄ and the colour produced is quantified using a microplate reader. The colour generated is proportional to the concentration of α_1 AT present in the sample.

Supplied Materials:

- 1. Capture Antibody (A1AT-EIA-C):** One yellow-capped vial containing 0.5 ml of polyclonal affinity-purified anti- α_1 AT antibody for coating plates.
- 2. Detecting Antibody (A1AT-EIA-D):** One red-capped vial containing 0.5 ml of polyclonal peroxidase conjugated polyclonal anti- α_1 AT antibody for detection of captured α_1 AT.

Note: Antibodies are supplied in a 50% (v/v) glycerol solution for storage at -10 to -20°C. Keep vials tightly capped. Do not store in frost-free freezers.

Materials Required but not Provided:

- 1. Coating Buffer:** 50 mM Carbonate
1.59g of Na₂CO₃ and 2.93g of NaHCO₃ up to 1 litre. Adjust pH to 9.6. Store at 2-8°C up to 1 month.
- 2. PBS:** (base for wash buffer and blocking buffer)
8.0g NaCl, 1.15g Na₂HPO₄, 0.2g KH₂PO₄ and 0.2g KCl, up to 1 litre. Adjust pH to 7.4, if necessary. Store up to 1 month at 2-8°C, discard if there is evidence of microbial growth.
- 3. Wash Buffer:** PBS-Tween (0.1%,v/v)
To 1 litre of PBS add 1.0 ml of Tween-20.
Check that the pH is 7.4. Store at 2-8°C up to 1 week.
- 4. Blocking Buffer:** PBS-BSA (1%, w/v)
Dissolve 2.5 g of Bovine Serum Albumin (Sigma-RIA grade) in 200 ml of PBS. Adjust pH to 7.4, if required, then make up to 250 ml with PBS. Aliquot and store frozen at -20°C.
- 5. Sample Diluent:** HBS-BSA-T20
5.95g HEPES (free acid), 1.46 g NaCl, 2.5 g Bovine Serum Albumin (Sigma, RIA grade) dissolved in 200 ml H₂O. Add 0.25 ml of Tween-20, check and adjust pH to 7.2 with NaOH, then make up to a final volume of 250 ml with H₂O. Aliquot and store frozen at -20°C.
- 6. Substrate Buffer:** Citrate-Phosphate buffer pH 5.0
2.6g Citric acid and 6.9g Na₂HPO₄ up to a final volume of 500 ml with purified H₂O. Store at 2-8°C up to 1 month.
- 7. OPD Substrate:** (o-Phenylenediamine.2HCl) **TOXIC!**
(5mg tablets: Sigma # P-6912). Make up immediately before use. Dissolve 5mg OPD in 12 ml substrate buffer then add 12 μ l 30% H₂O₂. Do not store.
- 8. Stopping Solution:** 2.5 M H₂SO₄
Caution: VERY CORROSIVE! GENERATES HEAT ON DILUTION! Where stock sulphuric acid is 18 Molar, add 13.9 ml to 86 ml H₂O. Store at room temperature.

9. Other:

Microplates, 96-well Immulon 4-HBX (<http://www.labsystems.fi>)
Microplate washer (optional)
Microplate reader.

Assay Procedure:

1. Coating of plates:

Dilute the capture antibody 1/100 in coating buffer (preferably in a polypropylene tube) and immediately add 100 µl to every well in the plate. Incubate 2 hours @22°C or overnight at 2-8°C.

2. Blocking:

Empty contents of plate and add 150 µl of blocking buffer to every well and incubate **for 60 minutes** @ 22°C. Wash plate X 4 with wash buffer.

3. Samples:

Reference plasma is diluted 1/20,000 (100%) then serial 1/2's down to 1/640,000 (3.13%). Sample plasmas are diluted 1/40,000 and 1/80,000. All dilutions are made in HBS-BSA-T20 sample diluent. Apply 100 µl/well and incubate plate @ 22°C for **60 minutes**.

Wash plate X 4 with wash buffer.

4. Detecting Antibody:

Dilute the detecting antibody 1/100 in HBS-BSA-T20 sample diluent and apply 100 µl to each well. Incubate plate @ 22°C for 60 minutes.

Wash plate X 4 with wash buffer.

5. OPD Substrate:

Apply 100 µl of freshly prepared OPD substrate to every well. Allow colour to develop for **5-10 minutes** and then stop colour reaction with the addition of 50 µl/well of 2.5 M H₂SO₄. The plate can be read at wavelength of 490 nm.

Calculation of Results:

The construction of a proper reference curve is of no less importance than any other aspect of the assay. A reference curve should be constructed by plotting the known concentration of standards versus absorbance. This can be done manually using graph paper, or by using curve-fitting computer software. In our experience, the dose response curves of most immunoassays tend to be sigmoid in shape. Although linear regions can be identified within the curve, the best overall fit is often obtained using an algorithm that provides a weighted theoretical model of fit throughout the entire curve, such as a 4-parameter or 5-parameter logistic curve fit^{8,9}. In general, the simplest model that defines the concentration-response relationship should be used⁹.

The "back-fit" test is a simple and reliable method to determine if a curve-fitting method is appropriate. In this test, the apparent concentrations for the absorbance values of each standard point are read from the reference curve. The derived values are compared to the assigned values. An appropriate curve fitting method will produce derived values that closely match assigned values throughout the range of the curve, within user-defined limits⁶. The coefficient of determination (R^2) is a valuable indicator of the overall fit, but should not be used by itself in the selection of a curve fitting method, as a poor fit in a particular region of the curve may not be evident from this value alone^{8,9}.

In the quality control of this product we have determined that under the conditions described above, a reference curve that is constructed using serial dilutions of normal pooled plasma, will produce a correlation coefficient (R^2) of at least 0.980 using a log-log fit, and an R^2 of at least 0.990 using a 4-parameter logistic curve fit algorithm. However, the performance characteristics of in-house assays developed using this product in other laboratories may vary slightly from ours. Different curve fitting methods may be employed but we recommend that the back-fit test be applied as evidence that the fitting method is appropriate.

Technical Notes:

- This paired antibody product is intended to facilitate the end user in establishing an in-house immunoassay for research purposes only. It must not be used for diagnostic applications. Assay validation is the responsibility of the end user and should be done according to user-defined protocols⁹.
- Reference calibrators should be of the same matrix and anticoagulant as the samples to be tested (example serum or plasma, citrate or EDTA)
- Do not use samples diluted less than 1/1000, as falsely high readings may result.
- The optimal colour development time should be determined empirically as the time required to obtain an absorbance of at least 1.000 at 490 nm for the 100% reference point, not to exceed 20 minutes.
- Rheumatoid factor in samples may interfere in ELISA by binding to the capture and/or detecting antibodies.
- The wells should not be allowed to become dry. Keep plate covered or in a humid chamber during incubations.
- The capture antibody is supplied in a 50% glycerol solution and can be centrifuged briefly in a micro-centrifuge to gather residual reagent from the cap and walls of the tube.

References:

1. Johnson D, Travis J; Oxidative Inactivation of Human α -1-Proteinase Inhibitor; JBC 254, pp4022-4026, 1979.
2. Travis J, Johnson D; Human α -1-Proteinase Inhibitor; Methods in Enzymology, **80**, pp 754-765, 1981.
3. Heeb MJ, Griffin JH; Physiologic Inhibition of Human Activated Protein C by α -1-Trypsin Inhibitor; JBC 263, pp1163-11616, 1988.
4. Scott CF, Schapira M, James HL, Cohen AB, Colman RW; The Inactivation of Factor XIa by plasma protease inhibitors: Predominant role of α ₁protease inhibitor and protective effect of high molecular weight kininogen. J Clin Invest 69, pp 844, 1982.
5. Nix,B, Wild D, in Immunoassays, A Practical Approach, editor J.P. Gosling, pp. 239-261, Oxford University Press, 2000.
6. NCCLS. Evaluation of the Linearity of Quantitative Analytical Methods; Proposed Guideline – Second Edition. NCCLS Document EP6-P2 (ISBN 1-56238-446-5, NCCLS, Wayne, Pennsylvania, USA, 2001.
7. FDA Guidance for Industry. Bioanalytical Method Validation; May 2001, available on the internet: www.fda.gov/cder/guidance/index.htm